Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19

Zhu, Kewei

doi:10.1021/acsptsci.3c00134

Cited by 24 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the combination of lopinavir and ritonavir, commonly used for HIV treatment, has shown inhibitory activity on of COVID-19 protease in in vitro experiments, but has not demonstrated significant efficacy in clinical trials [ 28 ]. Although Paxlovid, an FDA-approved SARS-CoV-2 Mpro protease inhibitor, shows promise, it is still constrained by limitations such as supply constraints, high cost, and limited clinical evidence [ 29 ]. Therefore, this study aims to identify new active compounds from traditional Chinese medicine (TCM) to expand the range of antiviral therapeutic options against viral proteases.…”

Section: Discussionmentioning

confidence: 99%

Screening for Active Compounds of Acorus calamus against SARS-CoV-2 Viral Protease and Mechanism Prediction

Huang,

Li,

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

COVID-19, caused by SARS-CoV-2, has emerged as the most destructive emerging infectious disease of the 21st century. Vaccination is an effective method to combat viral diseases. However, due to the constant mutation of the virus, new variants may weaken the efficacy of vaccines. In the current field of new coronavirus research, viral protease inhibitors have emerged as a highly regarded therapeutic strategy. Nevertheless, existing viral protease inhibitors do not fully meet the therapeutic needs. Therefore, this paper turned to traditional Chinese medicine to explore new active compounds. This study focused on 24 isolated compounds from Acorus calamus L. and identified 8 active components that exhibited significant inhibitory effects on SARS-CoV-2 PLpro. Among these, the compound 1R,5R,7S-guaiane-4R,10R-diol-6-one demonstrated the best inhibitory activity with IC50 values of 0.386 ± 0.118 μM. Additionally, menecubebane B and neo-acorane A exhibited inhibitory activity against both Mpro and PLpro proteases, indicating their potential as dual-target inhibitors. The molecular docking results confirmed the stable conformations of these compounds with the key targets and their good activity. ADMET and Lipinski’s rule analyses revealed that all the small molecule ligands possessed excellent oral absorption properties. This study provides an experimental foundation for the discovery of promising antiviral lead compounds.

show abstract

Section: Discussionmentioning

confidence: 99%

Screening for Active Compounds of Acorus calamus against SARS-CoV-2 Viral Protease and Mechanism Prediction

Huang,

Li,

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…RdRp is highly conserved in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is an excellent target for the development of anti-SARS-CoV-2 agents Vicenti et al, 2021;Zhu, 2023a). Nucleoside analogs were considered candidate drugs for the treatment of coronavirus disease 2019 (COVID-19), and several nucleoside analogs were identified as promising anti-SARS-CoV-2 drugs based on satisfactory results of preclinical trials .…”

Section: Discussionmentioning

confidence: 99%

The Evolution in Pharmacology of Infectious Diseases: 2022

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

“…302 The dithia-7-azaspiro[4.4]nonane derivative 80 is a strong SARS-CoV-2 M pro inhibitor which was developed by Simcere Pharmaceutical. In association with ritonavir, 303 it has also been granted conditional market approval in China under the name Xiannuoxin/simnotrelvir 304–306 and the results of phase 1 clinical trials (NCT05339646) were reported recently. 307 The undisclosed SARS-CoV-2 M pro inhibitor ALG-097558 is developed by Aligos therapeutics, possibly without a co-administration of ritonavir and phase 1 clinical trials have been initiated (NCT05840952).…”

Section: Inhibitors Of the Sars-cov-2 Main Proteasementioning

confidence: 99%